Richard J. Ulevitch, PhD

Venture Partner

Richard J. Ulevitch, Ph.D. joined 5AM Ventures in February 2008 as a Venture Partner. Previously he was Chairman of 5AM’s Scientific Advisory Board while serving as Professor and Chairman of the Department of Immunology at The Scripps Research Institute in La Jolla, California. He remains as Professor and Chairman Emeritus at The Scripps Research Institute. For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease. He serves as a scientific advisor to Aravis Ventures, a European life science venture capital fund and previously served as an advisor to the Lombard Odier Immunology Fund, where he evaluated numerous biotechnology companies over a fifteen-year span. Dr. Ulevitch serves or has served on the Scientific Advisory Boards of Arvinas, Biodesy, Bird Rock Bio, Cidara (NASDAQ: CDTX), Cleave, Envoy (acquired by Takeda), Ideaya, Igenica, Ikaria (acquired by Mallinckrodt), Pulmatrix (NASDAQ: PULM) as well as on the Board of PhaseRx. Dr. Ulevitch received an A.B. from Washington and Jefferson College and a Ph.D. in Biochemistry from the University of Pennsylvania. Dr. Ulevitch is based in the San Francisco, CA office.